Loading quotes...
Forecast
| Buy |
2 |
| Hold |
1 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | 2023 | YoY |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | -23.2m | 30.35% |
| Net profit | -22.85m | 29.83% |
| EBITDA | -23.31m | 35.84% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €48.17k |
Number of shares | 4.85m |
52-week high/low | €2.23 - €0.0000894 |
| Dividends | No |
Beta | 1.88 |
P/E ratio | 0.00 |
PEG ratio | 0.00 |
P/B ratio | -0.01 |
P/S ratio | 0.00 |
Company profile
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
| Name | Panbela Therapeutics Aktie |
| CEO | Jennifer K. Simpson |
| Headquarters | Waconia,
mn USA |
| Website | |
| Industry | Chemicals |
| IPO | 01/01/2008 |
| Employees | 8 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | PBLA |
München | X70.MU |
